| Parameter | Value |
|---|---|
| Initial dose | 2.5 mg/kg IV |
| Repeat | q5 min PRN |
| Max (most cases) | 10 mg/kg |
| Post-crisis infusion | 1 mg/kg q4-6h × 24-48 h |
| OR stockpile (legacy) | 36 vials × 20 mg |
| OR stockpile (Ryanodex) | 3 vials × 250 mg |
Karlet, M. C. (2023). Musculoskeletal system anatomy, physiology, pathophysiology, and anesthesia management. In S. Elisha, J. S. Heiner, & J. J. Nagelhout (Eds.), Nurse anesthesia (7th ed., pp. 826-850). Elsevier.
Dantrolene is the definitive treatment for malignant hyperthermia, blocking calcium release from the sarcoplasmic reticulum through the RYR1 receptor (Douglas, 2019, p. 1126). The initial dose is 2.5 mg/kg IV, repeated every 5 to 10 minutes until tachycardia, hypercarbia, rigidity, and fever resolve, up to a practical maximum of 10 mg/kg, beyond which an alternate diagnosis should be considered (Douglas, 2019, pp. 1133-1134). After the crisis resolves, 1 mg/kg or more continues every 4 to 6 hours for 24 to 48 hours (Douglas, 2019, p. 1133).
Older Dantrium or Revonto vials hold 20 mg and need 60 mL of sterile water each, so a 70 kg initial dose is about 9 vials; each 250 mg Ryanodex vial reconstitutes in 5 mL, about 1 vial for the same dose (Douglas, 2019, pp. 1133-1134). Early dantrolene cuts MH mortality from about 80% to 4%, and the MH Hotline, 1-800-644-9737, is staffed 24 hours (Douglas, 2019, pp. 1128, 1134).
Douglas, M. J. (2019). Malignant hyperthermia. In Chestnut's obstetric anesthesia (6th ed., pp. 1118-1130). Elsevier.